Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18666130 | 0.82 | SIRT1 (0.35) | ABCB1GPR119EGLN2RAD51 | |
| SCHEMBL18665819 | 0.81 | RAD51 (0.40) | KMT2AMEN1ABCB1GPR119RAD51 | |
| SCHEMBL17048614 | 0.76 | KDM4E (0.45) | KMT2AMEN1GPR119 | |
| SCHEMBL18665796 | 0.76 | KDM4E (0.45) | KMT2AMEN1GPR119 | |
| SCHEMBL17048612 | 0.76 | KDM4E (0.45) | KMT2AMEN1GPR119 | |
| SCHEMBL122620 | 0.71 | KMT2A (0.41) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21665877 | 0.65 | CTSS (0.43) | KMT2APPARA | |
| SCHEMBL12522736 | 0.65 | ALDH1A1 (0.43) | KMT2AMEN1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL29219560 | 0.65 | ALDH1A1 (0.43) | KMT2AMEN1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL16962042 | 0.64 | KMT2A (0.50) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350173-B1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INT (DE) | 2020-02-12 | — | — | EP | disclosed |
| EP-3599234-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-10189776-B2 | Stereoselective process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| WO-2017046355-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189776-B2 | Stereoselective process | CYP4A11, CYP4B1, CYP3A4 | KMT2A 4603/4885MEN1 1402/4885CYP1A2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.